Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$156.23 +0.31%

+$0.46 today

Market cap
$6.29B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.09M

Average 0.17M

BLTE Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Belite Bio, IncNASDAQ: BLTE

Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other current liabilities remains negative

Q2 FY2026 other current liabilities was $14.95M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +69.2% a year.

Context

  • Other current liabilities amounted to 1.9% of total assets at the end of Q2 FY2026, up 1.9 pp from a year earlier.
  • Other current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.95M-3.5% QoQ
Last fiscal yearDec 2025
$2.21M+122.7% YoY
Year agoJun 2025
$0— since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+122.7%——
3-year CAGR+69.2%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
2.21M USD
Year-over-year change
+122.7%
4-year CAGR
+209.7%

Other Current Liabilities vs competitors

How BLTE compares with its peers on the latest reported figures

  • BLTE's Jun 2026 other current liabilities of $14.95M is the highest of the 6 companies compared; the peer median is $4.12M.
  • Other current liabilities amounts to 1.9% of total assets for BLTE, versus a peer median of 3.1%.
BLTE Competitors Peer median
Other Current Liabilities for BLTE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BLTEBelite Bio, IncJun 2026$14.95M —+69.2%1.9%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$8.89M +58.9%+20.6%3.1%
OCGNOcugen, Inc.Mar 2026$4.16M +12.8%+29.1%7.3%
IRDOpus Genetics, Inc.Mar 2026$4.12M -67.6%—6.2%
KLRSKalaris Therapeutics IncMar 2026$508K -15.6%+180.3%0.5%
KODKodiak Sciences Inc.Sep 2026$0 —-22.3%0.0%
Peer median (excluding BLTE) $4.12M-1.4%+24.8%3.1%

Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents17.34M42.09M88.16M31.68M352.93M
Short-term Investments000113.47M139.49M
Net Receivables23K19K867K594K718K
Inventory00000
Other Current Assets00005K
Total Current Assets17.43M42.81M89.94M147.07M494.27M
Property, Plant & Equipment (Net)94K1.35M1.3M965K777K
Goodwill00000
Intangible Assets031K3.3M3.99M4.92M
Long-term Investments0000280.17M
Tax Assets00000
Other Non-current Assets823K88K104K103K425K
Total Non-current Assets917K1.47M4.7M5.06M286.28M
Total Assets18.35M44.27M94.64M152.13M780.56M
Account Payables00000
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities24K456K876K992K2.21M
Total Current Liabilities1.64M2.1M3.63M6.05M9.88M
Long-term Debt31.81M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities31.81M668K578K261K188K
Total Liabilities33.44M2.77M4.21M6.31M10.07M
Common Stock1K3K3K3K4K
Retained Earnings(27.22M)(39.87M)(71.5M)(107.65M)(185.26M)
Accumulated OCI(196K)(392K)(374K)(660K)(536K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity(15.09M)41.5M90.43M145.82M770.49M
Total Debt31.81M866K886K537K429K
Net Debt14.46M(41.22M)(87.27M)(31.14M)(352.5M)

Belite Bio, Inc

NASDAQ:BLTE

Intrinsic Alpha fair value

Locked

Current Price

$156.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.